Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome
This study has been completed.
Information provided by:
First received: May 23, 2011
Last updated: June 9, 2011
Last verified: March 2006
The hypotheses of this study were that:
- HIV lipodystrophy is associated with psychological morbidity relating to body image, anxiety and depression.
- Treatment of HIV lipodystrophy using autologous fat transfer, polylactic acid or Bio-alcamid, is associated with an improvement in psychological morbidity and anatomical volume of treated areas.
- The DI3D system is a valid and reproducible method of recording and measuring facial 3-D volume.
HIV-Associated Lipodystrophy Syndrome
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Psychological Morbidity and Facial Volume in HIV Lipodystrophy:|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by NHS Lothian:
Primary Outcome Measures:
- measurement of 3-D facial volume [ Time Frame: 2 years ] [ Designated as safety issue: No ]3-D facial camera
Secondary Outcome Measures:
- psychological outcome [ Time Frame: 2 years ] [ Designated as safety issue: No ]derriford appearance scale hospital anxiety and depression scale
|Study Start Date:||August 2006|
|Study Completion Date:||July 2009|
|Primary Completion Date:||July 2009 (Final data collection date for primary outcome measure)|
autologous fat transfer
patients received fat transfer for HIV lipodystrophy
treatment with polylactic acid (PLA) for HIV lipodystrophy
Contacts and Locations